PTGER2 and early-onset autosomal dominant Alzheimer disease: Inhibiting EP2 or EP4 activity has been promising in diverse disease models for inflammation [14], demyelination [56], cognition [48], epileptic seizures [49], and Alzheimer’s disease pathology [23].